Moreover, genetically or pharmaceutically inhibition of SREBP1, ACC or FAS in GBM has been shown to significantly induce cell death, suggesting that SREBP1 is a promising therapeutic target in GBM [28]. The gene discussed is FAS; the disease is glioblastoma.